Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Influenza Hemagglutinin mRNA vaccine · 1 trial · 2 indications
Number of participants with unsolicited systemic immediate adverse events (AEs)
Number of participants with solicited injection site reactions
Number of participants with solicited systemic reactions
Number of participants with unsolicited AEs
Number of participants with medically attended adverse events (MAAE)s
Number of participants with serious adverse events (SAEs)
Number of participants with out-of-range biological test results
| Arm | Type | Description |
|---|---|---|
| sentinel cohort 1 | EXPERIMENTAL | 20 Participants in each age group will receive either Influenza hemagglutinin mRNA vaccine candidate dose 1 or dose 2 and half number of the participants in each age group also receiving the RIV4 control |
| sentinel cohort 2 | EXPERIMENTAL | 20 Participants in each age group will receive either Influenza hemagglutinin mRNA vaccine candidate dose 3 or dose 4 and half number of the participants in each age group also receiving the RIV4 control |
| sentinel cohort 3 | EXPERIMENTAL | 10 Participants in each age group will receive Influenza hemagglutinin mRNA vaccine candidate dose 5 with half of the participants in each age group also receiving the RIV4 control |
| main cohort 1 | EXPERIMENTAL | 40 Participants in each age group will receive either Influenza hemagglutinin mRNA vaccine candidate dose 1 or dose 2 and half number of the participants in each age group also receiving the RIV4 control |
| main cohort 2 | EXPERIMENTAL | 40 Participants in each age group will receive either Influenza hemagglutinin mRNA vaccine candidate dose 3 or dose 4 and half number of the participants in each age group also receiving the RIV4 control |
| main cohort 3 | EXPERIMENTAL | 20 Participants in each age group will receive Influenza hemagglutinin mRNA vaccine candidate dose 5, and half number of the participants in each age group also receiving the RIV4 control |
| Name | Type | Description |
|---|---|---|
| Influenza Hemagglutinin mRNA vaccine | BIOLOGICAL | Pharmaceutical form:Solution for injection-Route of administration:IM injection |
| Quadrivalent Recombinant Influenza Vaccine | BIOLOGICAL | Pharmaceutical form:Solution for injection-Route of administration:IM injection |
Inclusion Criteria: * Having given written informed consent prior to undertaking any study-related procedure. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: * Any subject who, in the judgment of the Investigator, is likely to be noncompliant dur...
Influenza Hemagglutinin mRNA vaccine is an investigational vaccine being developed for the prevention of influenza. It is designed to encode the influenza hemagglutinin protein to elicit an immune response. The vaccine is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Influenza Hemagglutinin mRNA vaccine is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical trials to evaluate the safety and immunogenicity of this investigational vaccine for influenza.
Influenza Hemagglutinin mRNA vaccine is in Phase 1 clinical development. It is an investigational vaccine and has not yet received regulatory approval. The Phase 1 trial has been completed, and the vaccine remains under evaluation for safety and immunogenicity in adult participants.
Influenza Hemagglutinin mRNA vaccine has been studied in one completed Phase 1 clinical trial, registered as NCT06118151. This trial assessed the safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in 388 adult participants aged 18 years and older in the United States.
Influenza Hemagglutinin mRNA vaccine is an investigational mRNA-based vaccine designed to prevent influenza, whereas traditional flu shots are typically inactivated or live attenuated vaccines. This mRNA vaccine encodes the influenza hemagglutinin protein to stimulate an immune response, but it is not yet approved and remains in clinical development.